Are atypical antipsychotic drugs also atypical antidepressants?

References

• Parker G, Roy K, Hadzi-Pavlovic D. Psychotic (delusional) depression. a meta-analysis of physical treatments. Journal of Affective Disorders 1992; 1: 17–24
   Web of Science ®Google Scholar
• Parker G, Mitchell P, Wilhelm K, Menkes K, Snowdon J, Schweitzer I, et al. Are the newer antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review. Australian and New Zealand Journal of Psychiatry 1999; 33: 874–881
   PubMed Web of Science ®Google Scholar
• Robertson M M, Trimble M R. Neuroleptics as antidepressants. Neuropharmacology 1981; 20: 1335–1336
   PubMed Web of Science ®Google Scholar
• Prien R F. Maintenance therapy. Handbook of affective disorders, E S Paykel. Churchill Livingstone, Edinburgh 1992
   Google Scholar
• Glazer W M. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. Journal of Clinical Psychiatry 2000; 61: 16–21
   PubMed Web of Science ®Google Scholar
• Arnt J, Sci D, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63–101
   PubMed Web of Science ®Google Scholar
• McElroy S L, Dessain E C. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder and schizophrenia. Journal of Clinical Psychiatry 1991; 52: 411–414
   PubMed Web of Science ®Google Scholar
• Banov M D, Zarate C A, Tohen M. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. Journal of Clinical Psychiatry 1994; 55: 295–300
   PubMed Web of Science ®Google Scholar
• Naber D, Hippius H. The European experience with the use of clozapine. Hospital and Community Psychiatry 1990; 41: 886
   PubMedGoogle Scholar
• Tohen M, Zarate C A. Antipsychotic agents and bipolar disorder. Journal of Clinical Psychiatry 1998; 59: 38–48
   PubMed Web of Science ®Google Scholar
• Muller-Seicheneder F, Muller M J, Hillert A. Risperidone versus haloperidol and amitriptyline in the treatment of patients with combined psychotic and depressive syndrome. Journal of Clinical Psychopharmacology 1998; 18: 111–120
   PubMed Web of Science ®Google Scholar
• Lane H Y, Chu W C, Chang W H. Risperidone monotherapy for mania and depression. American Journal of Psychiatry 1999; 156: 115
   PubMed Web of Science ®Google Scholar
• Lane H Y, Chang W H. Risperidone monotherapy for psychotic depression unresponsive to other treatments. Journal of Clinical Psychiatry 1998; 59: 624
   PubMed Web of Science ®Google Scholar
• O'Conner M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. Journal of Clinical Psychopharmacology 1998; 18: 89–91
   PubMed Web of Science ®Google Scholar
• Ostroff R B, Nelson J C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Journal of Clinical Psychiatry 1999; 60: 256–259
   PubMed Web of Science ®Google Scholar
• Welner M. Risperidone plus a monoamine oxidase inhibitor for agitated depression crisis. Journal of Clinical Psychopharmacology 1996; 16: 460–461
   PubMed Web of Science ®Google Scholar
• Tran P V, Hamilton S H, Kuntz A J. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997; 17: 407–418
   PubMed Web of Science ®Google Scholar
• Tollefson G D, Sanger T M, Beasley C M, Tran P V. A doubleblind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry 1998; 43: 803–810
   PubMed Web of Science ®Google Scholar
• Rothschild A J, Bates K S, Boehringer K L, Syed A. Olanzapine response in psychotic depression. Journal of Clinical Psychiatry 1999; 60: 116–118
   PubMed Web of Science ®Google Scholar
• Malhi G S, Checkley S A. Olanzapine in the treatment of psychotic depression. British Journal of Psychiatry 1999; 174: 460
   PubMed Web of Science ®Google Scholar
• Shelton R, Tollefson G D, Tohen M. Safety and efficacy of olanzapine plus fluoxetine in the treatment of major depressive disorder. Schizophrenia Research 1999; 36: 1–3
   PubMed Web of Science ®Google Scholar
• Weisler R H, Ahearn E P, Davidson J R, Wallace C D. Adjunctive use of olanzapine in mood disorders: five case reports. Annals of Clinical Psychiatry 1997; 9: 259–262
   PubMedGoogle Scholar
• Bymaster F P, Calligaro D O, Falcone J F, Marsh A D, Moore N A, Tye N C, et al. Radioceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87–96
   PubMed Web of Science ®Google Scholar
• Zhang W, Bymaster F P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 1999; 141: 267–278
   PubMed Web of Science ®Google Scholar
• Nyberg S, Farde L, Hallidin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997; 16: 1–7
   PubMed Web of Science ®Google Scholar
• Kasper S, Tauscher J, Kufferle B, Hesselmann B, Barnas C, Brucke T. IBZM-SPECT imaging of dopamine D2-receptors with typical and atypical antipsychotics. European Psychiatry 1998; 13: 9–14
   PubMed Web of Science ®Google Scholar
• Pilowsky L S, Bussato G F, Taylor M, Costa D C, Sharma T, Sigmundsson T, et al. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine –A 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 1996; 124: 148–153
   PubMed Web of Science ®Google Scholar
• Tollefson G D, Beasley C M, Tran P V, Street J S, Krueger J A, Tamura R N. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 1997; 154: 457–465
   PubMed Web of Science ®Google Scholar
• Vetulani J, Sulser F. Actions of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP generating system in limbic forebrain. Nature 1975; 257: 495–496
   PubMed Web of Science ®Google Scholar
• Peroutka S J, Snyder S H. Longterm antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science 1980; 210: 88–90
   PubMed Web of Science ®Google Scholar
• Meltzer H Y, Nash J F. Effects of antipsychotic drugs on serotonin receptors. Pharmacology Review 1991; 43: 587–604
   PubMed Web of Science ®Google Scholar
• Bussato G F, Kerwin R W. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. Journal of Psychopharmacology 1997; 11: 3–12
   PubMed Web of Science ®Google Scholar
• Simon A E, Aubry J M, Malky L, Bertschy G. Hypomania-like syndrome induced by olanzapine. International Journal of Clinical Psychopharmacology 1999; 14: 377–378
   PubMed Web of Science ®Google Scholar
• Lisoprawski A, Jouvent R. Dopaminergic agonists and effective dullness. Encephale 1989; 15: 197–200
   PubMedGoogle Scholar
• Willner P, Muscat R, Papp M. Chronic mild stress-induced anhedonia. A realistic animal model of depression. Neuroscience Biobehavior Review 1992; 16: 525–534
   PubMed Web of Science ®Google Scholar
• Muscat R, Papp M, Willner P. Antidepressant-like effects of dopamine agonists in an animal model of depression. Biological Psychiatry 1992; 31: 937–946
   PubMed Web of Science ®Google Scholar
• Papp M, Motyl E, Willner P. Pharmacological validation of the chronic mild stress model of depression. Journal of Pharmacology 1996; 296: 129–136
   Google Scholar
• Devaud L L, Hollingsworth E B, Cooper B R. Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin(2) receptor antagonist, ritanserin. Journal of Neurochemistry 1992; 59: 1459–1466
   PubMed Web of Science ®Google Scholar
• Li X M, Perry K W, Wong D T, Bymaster F P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 1998; 136: 156–161
   Web of Science ®Google Scholar
• Berman K F, Weinberger D R. The prefrontal cortex in schizophrenia and other neuropsychiatric disease: in vivo physiological correlates of cognitive deficits. Progress in Brain Research 1990; 85: 521–537
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic P S. The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Philosophical Transactions of the Royal Society of London –Series B: Biological Sciences 1996; 351: 445–1453
   Web of Science ®Google Scholar
• Pessia M, Jiang Z G, North R A, Johnson S W. Actionsof 5-hydroxy-tryptamine on ventral tegmental area neurones of the rat in vitro. Brain Research 1994; 654: 324–330
   PubMed Web of Science ®Google Scholar
• Parker G, Hadzi-Pavlovic D. Melancholia, a disorder of movement and mood: a phenomenological and neurobiological review, G Parker, D Hadzi-Pavlovic. Cambridge University Press, Cambridge 1996
   Google Scholar
• Wolfe N, Katz D I, Albert M L, Almozlino A, Durso R, Smith M C, Volicer L. Neuropsychological profile linked to low dopamine in Alzheimer's disease, major depression, and Parkinson's Disease. Journal of Neurology, Neurosurgery and Psychiatry 1990; 53: 915–917
   PubMed Web of Science ®Google Scholar
• Willner P. Dopaminergic mechanisms in depression and mania. Psychopharmacology: the fourth generation of progress, D J Bloom, FE, Kupfer. Raven, New York 1995; 921–931
   Google Scholar
• Brown A S, Gershon S. Dopamine and depression. Journal of Neural Transmission 1993; 91: 75–109
   PubMed Web of Science ®Google Scholar
• Rampello L, Nicoletti G, Raffael R. Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatrica Scandinavica 1991; 84: 552–554
   PubMed Web of Science ®Google Scholar
• Serra G, Forgione A, D'Aquila P S, Collu M, Fratta W, Gessa G L. Possible mechanism of antidepressant effect of L-sulpiride. Clinical Neuropharmacology 1990; 13: 76–83
   Web of Science ®Google Scholar
• Schwartz J C, Arrang J M, Garbarg M. Histamine. Psychopharmacology: the Fourth Generation of Progress, D J Bloom, FE, Kupfer. Raven Press, New York 1995; 397–405
   Google Scholar
• Moore N A, Calligaro D O, Wong D T. The pharmacology of olanzapine and other new antipsychotic agents. Current Opinion in Investigation Drugs 1993; 2: 281–293
   Google Scholar
• Zeng X P, Le F, Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. European Journal of Pharmacology 1997; 321: 349–354
   PubMed Web of Science ®Google Scholar
• Shelton R C, Tollefson G D, Tohen M, Stahl S, Gannon K S, Jacobs T G, et al. A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 2000; 158: 131–134
   Web of Science ®Google Scholar
• Robertson M M, Trimble M R. Major tranquillisers used as antidepressants. A review. Journal of Affective Disorders 1982; 4: 173–193
   PubMed Web of Science ®Google Scholar